cd4  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals cd4
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Cd4, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd4/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd4 - by Bioz Stars, 2024-09
    93/100 stars

    Images

    1) Product Images from "Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies"

    Article Title: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies

    Journal: Nature Communications

    doi: 10.1038/s41467-022-33282-0

    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Figure Legend Snippet: a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.

    Techniques Used: Staining, Immunohistochemistry

    control sirna  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology control sirna
    Control Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/control sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    control sirna - by Bioz Stars, 2024-09
    93/100 stars

    Images

    cd4  (Novus Biologicals)


    Bioz Verified Symbol Novus Biologicals is a verified supplier
    Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals cd4
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Cd4, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd4/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd4 - by Bioz Stars, 2024-09
    93/100 stars

    Images

    1) Product Images from "Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies"

    Article Title: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies

    Journal: Nature Communications

    doi: 10.1038/s41467-022-33282-0

    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Figure Legend Snippet: a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.

    Techniques Used: Staining, Immunohistochemistry

    clusterin sirna reagents  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology clusterin sirna reagents
    Clusterin Sirna Reagents, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clusterin sirna reagents/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clusterin sirna reagents - by Bioz Stars, 2024-09
    93/100 stars

    Images

    si clusterin  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology si clusterin
    Si Clusterin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/si clusterin/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    si clusterin - by Bioz Stars, 2024-09
    93/100 stars

    Images

    clu sirna  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology clu sirna
    Clu Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clu sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clu sirna - by Bioz Stars, 2024-09
    93/100 stars

    Images

    clusterin sirna  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology clusterin sirna
    Clusterin Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clusterin sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clusterin sirna - by Bioz Stars, 2024-09
    93/100 stars

    Images

    clusterin sirna  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology clusterin sirna
    Brain Microenvironment-Induced Down-Regulation of DNMT1 Reactivates GAD1 Expression. A, qRT-PCR of DNMT1 mRNA expression after 48 hours co-culture with either CAF or glia cells. (left) MDA-MB-231; (right) A375SM. B, qRT-PCR of DNMT1 mRNA expression of MDA-MB-231 cultured either with 100% conditioned media from either CAF or glia cells or 50% mix of conditioned media and fresh media. C, Cytokine screen of glia and CAF conditioned media. (left) MA plot of Log [mean expression of Glia/CAF] of 73 cytokines analyzed. *: differentially expressed cytokines (adjusted p < 0.1) (right) Heatmap of differentially expressed cytokines. D, Network analysis of differentially expressed cytokines. E, Impact of extracellular <t>clusterin</t> on DNMT1 and GAD1 expression. (left) Cytokine expression profile of clusterin in conditioned media from CAFs or glia cells. (right) qPCR of GAD1 and DNMT1 mRNA expression in MDA-MB-231 cells treated with control or 200 ng of clusterin. F, qRT-PCR of GAD1 and DNMT1 mRNA expression in tumor cells genetic knockdown of glia derived-clusterin. (left) qRT-PCR of clusterin mRNA expression in glia cells. (right) qRT-PCR of GAD1 and DNMT1 mRNA expression in MDA-MB-231 cells co-cultured with control glia or siClusterin glia cells. G, qRT-PCR of mRNA levels in tumor cells after 48 hours co-culture with primary glia cells. Prior to co-culture, tumor cells were transfected with either vector control or DNMT1 over expression plasmid for 24 hours. (left) DNMT1 mRNA expression; (right) GAD1 mRNA expression under glia co-culture. H, Proliferation of MDA-MB-231 cells after DNMT1 overexpression and co-culture with glia cells for 48 hours.
    Clusterin Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clusterin sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clusterin sirna - by Bioz Stars, 2024-09
    93/100 stars

    Images

    1) Product Images from "GAD1 Upregulation Programs Aggressive Features of Cancer Cell Metabolism in the Brain Metastatic Microenvironment"

    Article Title: GAD1 Upregulation Programs Aggressive Features of Cancer Cell Metabolism in the Brain Metastatic Microenvironment

    Journal: Cancer research

    doi: 10.1158/0008-5472.CAN-16-2289

    Brain Microenvironment-Induced Down-Regulation of DNMT1 Reactivates GAD1 Expression. A, qRT-PCR of DNMT1 mRNA expression after 48 hours co-culture with either CAF or glia cells. (left) MDA-MB-231; (right) A375SM. B, qRT-PCR of DNMT1 mRNA expression of MDA-MB-231 cultured either with 100% conditioned media from either CAF or glia cells or 50% mix of conditioned media and fresh media. C, Cytokine screen of glia and CAF conditioned media. (left) MA plot of Log [mean expression of Glia/CAF] of 73 cytokines analyzed. *: differentially expressed cytokines (adjusted p < 0.1) (right) Heatmap of differentially expressed cytokines. D, Network analysis of differentially expressed cytokines. E, Impact of extracellular clusterin on DNMT1 and GAD1 expression. (left) Cytokine expression profile of clusterin in conditioned media from CAFs or glia cells. (right) qPCR of GAD1 and DNMT1 mRNA expression in MDA-MB-231 cells treated with control or 200 ng of clusterin. F, qRT-PCR of GAD1 and DNMT1 mRNA expression in tumor cells genetic knockdown of glia derived-clusterin. (left) qRT-PCR of clusterin mRNA expression in glia cells. (right) qRT-PCR of GAD1 and DNMT1 mRNA expression in MDA-MB-231 cells co-cultured with control glia or siClusterin glia cells. G, qRT-PCR of mRNA levels in tumor cells after 48 hours co-culture with primary glia cells. Prior to co-culture, tumor cells were transfected with either vector control or DNMT1 over expression plasmid for 24 hours. (left) DNMT1 mRNA expression; (right) GAD1 mRNA expression under glia co-culture. H, Proliferation of MDA-MB-231 cells after DNMT1 overexpression and co-culture with glia cells for 48 hours.
    Figure Legend Snippet: Brain Microenvironment-Induced Down-Regulation of DNMT1 Reactivates GAD1 Expression. A, qRT-PCR of DNMT1 mRNA expression after 48 hours co-culture with either CAF or glia cells. (left) MDA-MB-231; (right) A375SM. B, qRT-PCR of DNMT1 mRNA expression of MDA-MB-231 cultured either with 100% conditioned media from either CAF or glia cells or 50% mix of conditioned media and fresh media. C, Cytokine screen of glia and CAF conditioned media. (left) MA plot of Log [mean expression of Glia/CAF] of 73 cytokines analyzed. *: differentially expressed cytokines (adjusted p < 0.1) (right) Heatmap of differentially expressed cytokines. D, Network analysis of differentially expressed cytokines. E, Impact of extracellular clusterin on DNMT1 and GAD1 expression. (left) Cytokine expression profile of clusterin in conditioned media from CAFs or glia cells. (right) qPCR of GAD1 and DNMT1 mRNA expression in MDA-MB-231 cells treated with control or 200 ng of clusterin. F, qRT-PCR of GAD1 and DNMT1 mRNA expression in tumor cells genetic knockdown of glia derived-clusterin. (left) qRT-PCR of clusterin mRNA expression in glia cells. (right) qRT-PCR of GAD1 and DNMT1 mRNA expression in MDA-MB-231 cells co-cultured with control glia or siClusterin glia cells. G, qRT-PCR of mRNA levels in tumor cells after 48 hours co-culture with primary glia cells. Prior to co-culture, tumor cells were transfected with either vector control or DNMT1 over expression plasmid for 24 hours. (left) DNMT1 mRNA expression; (right) GAD1 mRNA expression under glia co-culture. H, Proliferation of MDA-MB-231 cells after DNMT1 overexpression and co-culture with glia cells for 48 hours.

    Techniques Used: Expressing, Quantitative RT-PCR, Co-Culture Assay, Cell Culture, Derivative Assay, Transfection, Plasmid Preparation, Over Expression

    GAD1-Mediated Glutamine Metabolism Enables Brain Metastatic Outgrowth. A, (top) Representative images of A375SM brain metastatic tumors arising from 1:1 mix of tumor cells expressing either control (labeled with GFP) or GAD1 targeted shRNA (labeled with RFP), (bottom) Quantification of metastatic incidence. B, (top) Representative images of MDA-MB-231 brain metastatic tumors with/without GAD1 knockdown, (bottom) Quantification of metastatic incidence. C, Representative images of brain metastatic tumors arising from arising from A375SM cell after treated with vehicle control or vigabatrin (4 mg/kg) for seven days beginning at seven days post injection. D, Reduction of metastatic tumor lesions by vigabatrin. (left) representative images of haemoxyolin and eosin staining of metastatic tumors treated with either control or vigabatrin (4 mg/kg); (right) Quantification of stained tumors per section. E, Ki-67 immunohistochemistry staining of tumors arising in mice treated with either vehicle control or vigabatrin (4 mg/kg). (left) Representative images of Ki-67 staining; (right) Quantification of ki-67 positive tumor cells per region of interest. F, Proposed model of brain microenvironment-induced tumor cell metabolic shifting via clusterin-mediated epigenetic upregulation of GAD1, which contributes to brain metastatic outgrowth.
    Figure Legend Snippet: GAD1-Mediated Glutamine Metabolism Enables Brain Metastatic Outgrowth. A, (top) Representative images of A375SM brain metastatic tumors arising from 1:1 mix of tumor cells expressing either control (labeled with GFP) or GAD1 targeted shRNA (labeled with RFP), (bottom) Quantification of metastatic incidence. B, (top) Representative images of MDA-MB-231 brain metastatic tumors with/without GAD1 knockdown, (bottom) Quantification of metastatic incidence. C, Representative images of brain metastatic tumors arising from arising from A375SM cell after treated with vehicle control or vigabatrin (4 mg/kg) for seven days beginning at seven days post injection. D, Reduction of metastatic tumor lesions by vigabatrin. (left) representative images of haemoxyolin and eosin staining of metastatic tumors treated with either control or vigabatrin (4 mg/kg); (right) Quantification of stained tumors per section. E, Ki-67 immunohistochemistry staining of tumors arising in mice treated with either vehicle control or vigabatrin (4 mg/kg). (left) Representative images of Ki-67 staining; (right) Quantification of ki-67 positive tumor cells per region of interest. F, Proposed model of brain microenvironment-induced tumor cell metabolic shifting via clusterin-mediated epigenetic upregulation of GAD1, which contributes to brain metastatic outgrowth.

    Techniques Used: Expressing, Labeling, shRNA, Injection, Staining, Immunohistochemistry

    atcc 43689  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    ATCC atcc 43689
    Atcc 43689, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc 43689/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    atcc 43689 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    sirna approach  (Santa Cruz Biotechnology)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology sirna approach
    Sirna Approach, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sirna approach/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sirna approach - by Bioz Stars, 2024-09
    93/100 stars

    Images

    atcc 43689  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    ATCC atcc 43689
    Atcc 43689, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc 43689/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    atcc 43689 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • cd4  (Novus Biologicals)
    93
    Novus Biologicals cd4
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Cd4, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd4/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd4 - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier
    control sirna  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology control sirna
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Control Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/control sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    control sirna - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier
    clusterin sirna reagents  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology clusterin sirna reagents
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Clusterin Sirna Reagents, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clusterin sirna reagents/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clusterin sirna reagents - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier
    si clusterin  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology si clusterin
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Si Clusterin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/si clusterin/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    si clusterin - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier
    clu sirna  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology clu sirna
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Clu Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clu sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clu sirna - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier
    clusterin sirna  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology clusterin sirna
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Clusterin Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clusterin sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    clusterin sirna - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier
    atcc 43689  (ATCC)
    86
    ATCC atcc 43689
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Atcc 43689, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atcc 43689/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    atcc 43689 - by Bioz Stars, 2024-09
    86/100 stars
    		  Buy from Supplier
    sirna approach  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology sirna approach
    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of <t>CD4</t> and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
    Sirna Approach, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sirna approach/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sirna approach - by Bioz Stars, 2024-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies

    doi: 10.1038/s41467-022-33282-0

    Figure Lengend Snippet: a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c , d , k The GSEA enrichment analysis of TCR signaling pathway in DOS ( c ), XELOX ( d , n (S) = 25, n (NS) = 20), XELOX of BPRC cohort ( k ), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e , f , l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD ( n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.

    Article Snippet: A standard immunohistochemistry (IHC) protocol was followed to stain the tumor tissue samples using the rabbit polyclonal antibody against CTSE (1:100, Signalway Antibody, catalog No: 35666), and the rabbit polyclonal antibody against TKTL1 (1:500, Novus Biologicals, catalog No: NBP1-31674), the rabbit antibody monoclonal against CD4 (1:250, GeneTech, catalog No: GT219107), the mouse monoclonal antibody against CD8 (1:300, Leica, catalog NO: PA0183).

    Techniques: Staining, Immunohistochemistry